• About Us
  • Business Model
  • Intellectual Property
  • Team
  • Publications
  • Contact

News

TCF: Avammune Therapeutics attending the IO360 Conference February 2020 in New York

Feb 26, 2020


SITC: Avammune Therapeutics team attending the Society for Immunotherapy for Cancer 2019 Annual Meeting.

Nov 6, 2019


Immuno-Oncology Summit: Avammune Therapeutics STING modulator program presented at Immunooncology Summit Boston 2019.

Aug 8, 2019


PRWeb: Avammune Therapeutics announces Series A funding and formation of Scientific Advisory Board.

Jul 9, 2019


Bangalore Mirror Bureau: These two collegemates are making drugs for rare diseases that afflict mostly children.

Jul 1, 2019


Forbes India: Tackling pharma's rare challenges - Those afflicted by orphan diseases are rare; companies looking for orphan drugs are rarer still. Among them is Aten Porus that has found early success in this uncharted region of medical science.

Jun 11, 2018


BW: Oraxion executes an Exclusive Option Agreement on ORX-301 for treating NPC and FSGS with the potential to reach over US$125 million in payments. (We would like to dedicate this milestone in memory of our recently departed friend and colleague Soniya Johny who was instrumental in bringing this work to fruition).

Feb 5, 2018


YourStory: This Purdue University grad aims to find drugs for rare genetic disorders.

Apr 27, 2017


ET Bureau: Aten Porus Lifesciences: Firm is developing drugs to fight a host of rare diseases globally. To begin with, the duo decided to focus on Niemann-Pick Type C (NPC) disorder that’s also referred to as Childhood Alzheimer’s.

Feb 03, 2017


Back Home
© 2016-2020 Aten Porus Lifesciences